Skip to main content
Open Access Publications from the University of California

UC Irvine

UC Irvine Previously Published Works bannerUC Irvine

Effect of polymorphism of the beta(2)-adrenergic receptor on response to regular use of albuterol in asthma.

  • Author(s): Israel, E
  • Drazen, JM
  • Liggett, SB
  • Boushey, HA
  • Cherniack, RM
  • Chinchilli, VM
  • Cooper, DM
  • Fahy, JV
  • Fish, JE
  • Ford, JG
  • Kraft, M
  • Kunselman, S
  • Lazarus, SC
  • Lemanske, RF
  • Martin, RJ
  • McLean, DE
  • Peters, SP
  • Silverman, EK
  • Sorkness, CA
  • Szefler, SJ
  • Weiss, ST
  • Yandava, CN
  • National Heart, Lung, and Blood Institute's Asthma Clinical Research Network
  • et al.

Published Web Location Commons 'BY' version 4.0 license


Regular use of inhaled beta-adrenergic agonists may have adverse effects in some asthma patients. Polymorphisms of the beta(2)-adrenergic receptor (beta(2)-AR) can affect its regulation; however, results of smaller studies of the effects of such polymorphisms on response to beta-agonist therapy have been inconsistent.


We examined the possible effects of polymorphisms at codons 16 (beta(2)-AR-16) and 27 (beta(2)-AR-27) on response to albuterol by genotyping 190 asthmatics who had participated in a trial of regular versus as-needed albuterol use.


During the 16-week treatment period, patients homozygous for arginine (Arg/Arg) at beta(2)-AR-16 who used albuterol regularly had a small decline in morning peak expiratory flow (AM PEF). This effect was magnified during a 4-week run-out period, when all patients returned to as-needed albuterol only. By the end of the study, Arg/Arg subjects who had used albuterol regularly had an AM PEF 30.5 +/- 12.1 liters/min lower (p = 0.012) than Arg/Arg patients who had used albuterol as needed only. Subjects homozygous for glycine at beta(2)-AR-16 showed no such decline. Evening PEF also declined in the Arg/Arg regular but not in as-need albuterol users. No significant differences between regular and as-needed treatment were associated with polymorphisms at beta(2)-AR-27.


Polymorphisms of the beta(2)-AR may influence airway responses to regular inhaled beta-agonist treatment.

Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.

Main Content
Current View